Cancer Chemotherapy and Pharmacology

Article	Citations
Tumor microenvironment promotes breast cancer chemoresistance	135
Disulfiram: a novel repurposed drug for cancer therapy	71
Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells	54
Involvement of cytochrome P450 enzymes in inflammation and cancer: a review	54
Artemisinin-type drugs for the treatment of hematological malignancies	36
Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer	36
Reactive oxygen species in cancer: a paradox between pro- and anti-tumour activities	32
Aloin alleviates doxorubicin-induced cardiotoxicity in rats by abrogating oxidative stress and pro-inflammatory cytokines	28
Anticancer effects of brusatol in nasopharyngeal carcinoma through suppression of the Akt/mTOR signaling pathway	26
Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway	25
The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis	24
Berberine chloride suppresses non-small cell lung cancer by deregulating Sin3A/TOP2B pathway in vitro and in vivo	24
The role of the glutamine transporter ASCT2 in antineoplastic therapy	24
Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Child	23
EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer	20
Irinotecan-induced intestinal mucositis in mice: a histopathological study	20
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer	20
Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug–drug interaction predictions using a PBPK approach	20
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE)	19
CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model	18
Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma	18
Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug	18
HOTAIR promotes paclitaxel resistance by regulating CHEK1 in ovarian cancer	17
Anlotinib combined with temozolomide suppresses glioblastoma growth via mediation of JAK2/STAT3 signaling pathway	17
Human placental extract ameliorates methotrexate-induced hepatotoxicity in rats via regulating antioxidative and anti-inflammatory responses	17

FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway	17
Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1	17
Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment	16
Clinical utility of circulating tumor-associated cells to predict and monitor chemo-response in solid tumors	16
Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases	16
Translational model of melphalan-induced gut toxicity reveals drug-host-microbe interactions that drive tissue injury and fever	16
Panobinostat penetrates the blood–brain barrier and achieves effective brain concentrations in a murine model	16
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies	15
Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells	15
Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types	15
Repurposed antipsychotic chlorpromazine inhibits colorectal cancer and pulmonary metastasis by inducing G2/M cell cycle arrest, apoptosis, and autophagy	15
Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer	14
Inhibition of autophagy by chloroquine enhances the antitumor activity of gemcitabine for gallbladder cancer	14
Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors	14
Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma	14
Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study	14
Time-dependent population PK models of single-agent atezolizumab in patients with cancer	14
Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology	13
MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism	13
Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer	13
Pharmacokinetics of preoperative intraperitoneal 5-FU in patients with pancreatic ductal adenocarcinoma	13
Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study	13
A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers	13
PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via transcriptional regulation of EPAS1	13
New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine	13
The gut microbiota attenuates muscle wasting by regulating energy metabolism in chemotherapy-induced malnutrition rats	13
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial	13
Foretinib induces G2/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition	13
Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function	13
Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours	12
Influences of preoperative metformin on immunological factors in early breast cancer	12
Interactions between natural products and cancer treatments: underlying mechanisms and clinical importance	12
Evaluation of drug–drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML)	12
A Phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX02 to reference CN- and EU-sourced trastuzumab in healthy subjects	12
Aripiprazole prevents from development of vincristine-induced neuropathic nociception by limiting neural NOS overexpression and NF-kB hyperactivation	12
Targeting cPLA2α inhibits gastric cancer and augments chemotherapy efficacy via suppressing Ras/MEK/ERK and Akt/β-catenin pathways	11
A phase I study of intravenous fenretinide (4-HPR) for patients with malignant solid tumors	11
Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer	11
A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy	11
Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis	11
Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota	11
Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib	11
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients	10
Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results	10
Drug interactions with Bruton’s tyrosine kinase inhibitors: clinical implications and management	10
Sorafenib exposure and its correlation with response and safety in advanced hepatocellular carcinoma: results from an observational retrospective study	10
Disulfiram/copper induces antitumor activity against gastric cancer cells in vitro and in vivo by inhibiting S6K1 and c-Myc	10
Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma	10
Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment	10
Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8+ T cell augmentation	10

Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma	10
Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors	10
Pegylated liposomal doxorubicin-induced renal toxicity in retroperitoneal liposarcoma: a case report and literature review	10
Exposure–response analysis of endoxifen serum concentrations in early-breast cancer	10
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma	9
ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy	9
Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach	9
The use of vitamin E in preventing taxane-induced peripheral neuropathy	9
Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma	9
Zileuton inhibits arachidonate-5-lipoxygenase to exert antitumor effects in preclinical cervical cancer models	9
Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients	9
Use of cucurbitacins for lung cancer research and therapy	9
Anticancer potential of metformin: focusing on gastrointestinal cancers	9
Variants of carboxylesterase 1 have no impact on capecitabine pharmacokinetics and toxicity in capecitabine plus oxaliplatin treated-colorectal cancer patients	9
Comparative efficacy and safety of trastuzumab biosimilars to the reference drug: a systematic review and meta-analysis of randomized clinical trials	9
MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma	9
Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation	9
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer	9
Pharmacokinetics of tablet and liquid formulations of oral 6-mercaptopurine in children with acute lymphoblastic leukemia	9
Physiologically based pharmacokinetic modeling and simulation to predict drug–drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia	9
Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients	9
Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects	9
Beta-adrenergic blocker inhibits oral carcinogenesis and reduces tumor invasion	9
ATF4-mediated microRNA-145/HDAC4/p53 axis affects resistance of colorectal cancer cells to 5-fluorouracil by regulating autophagy	9
MEK inhibition overcomes everolimus resistance in gastric cancer	9
A systematic review of inter-individual differences in the DNA repair processes involved in melphalan monoadduct repair in relation to treatment outcomes	8
YLZ-F5, a novel polo-like kinase 4 inhibitor, inhibits human ovarian cancer cell growth by inducing apoptosis and mitotic defects	8
A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy	8
Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers	8
C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma	8
Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors	8
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach	8
5-Fluorouracil disrupts ovarian preantral follicles in young C57BL6J mice	8
Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients	8
Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas	8
Population pharmacokinetics–pharmacodynamics of sunitinib in pediatric patients with solid tumors	8
A phase I dose-escalation study of the polyamine analog PG-11047 in patients with advanced solid tumors	8
Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer	8
The effects of two gold-N-heterocyclic carbene (NHC) complexes in ovarian cancer cells: a redox proteomic study	8
Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment	8
Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti–programmed cell death protein-1 (PD-1) antibody, in human cancer models	8
Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma	8
UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells	8
First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer	8
Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer	7
Association between gene polymorphism and adverse effects in cancer patients receiving docetaxel treatment: a meta-analysis	7
Urine NGAL and KIM-1: tubular injury markers in acute lymphoblastic leukemia survivors	7
Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer	7
The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia	7
Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway	7
Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors	7
Cardiovascular toxicity of breast cancer treatment: an update	7
Population pharmacokinetic analysis of entrectinib in pediatric and adult patients with advanced/metastatic solid tumors: support of new drug application submission	7
Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1	7
Galeterone sensitizes breast cancer to chemotherapy via targeting MNK/eIF4E and β-catenin	7
Oncology dose optimization paradigms: knowledge gained and extrapolated from approved oncology therapeutics	7
Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice—a prospective single-center trial	7
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer	7
CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone	7
Probenecid increases renal retention and antitumor activity of DFMO in neuroblastoma	7
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers	7
miR-331-3p is involved in glucocorticoid resistance reversion by rapamycin through suppression of the MAPK signaling pathway	7
A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment	7
Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype	7
An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib	7
Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1–XPF-mediated DNA repair	7
Absorption, metabolism and excretion of [14C]-sotorasib in healthy male subjects: characterization of metabolites and a minor albumin-sotorasib conjugate	7
The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update	7
Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6–Cyclin D–Rb pathway	7
Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine	7
Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies	6
Downregulation of SELENBP1 enhances oral squamous cell carcinoma chemoresistance through KEAP1–NRF2 signaling	6
Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses	6
Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system	6
Population pharmacokinetic model development and exposure–response analysis of vincristine in patients with malignant lymphoma	6
Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy	6
An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure	6
Targeted therapy of angiogenesis using anti-VEGFR2 and anti-NRP-1 nanobodies	6
Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors	6
A phase 1, open-label, drug–drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors	6

Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case–control study	6
A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors	6
Pharmacokinetics of alemtuzumab in pediatric patients undergoing ex vivo T-cell-depleted haploidentical hematopoietic cell transplantation	6
Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy	6
A phase Ι study to evaluate the application of photocyanine using pharmacokinetic and pharmacodynamic analysis in patients with malignancy	6
Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis	6
The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 st	6
Prediction of drug–drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling	6
Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl	6
Demethoxycucumin protects MDA-MB-231 cells induced bone destruction through JNK and ERK pathways inhibition	6
Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study	6
Effect of ceritinib on the pharmacokinetics of coadministered CYP3A and 2C9 substrates: a phase I, multicenter, drug–drug interaction study in patients with ALK + advanced tumors	6
All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma	6
Upregulation of TRIB2 by Wnt/β-catenin activation in BRAFV600E papillary thyroid carcinoma cells confers resistance to BRAF inhibitor vemurafenib	6
Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population	6
Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children’s Oncology Group Study ADVL06B1	6
Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression	6
The use of zebrafish model in prostate cancer therapeutic development and discovery	6
Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2– advanced breast cancer in Chinese women	6
Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations	6
An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer	6
Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast	6
Influence of genetic variants in asparaginase pathway on the susceptibility to asparaginase-related toxicity and patients' outcome in childhood acute lymphoblastic leukemia	6
A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers	6
Starting dose selection and dose escalation for oncology small molecule first-in-patient trials: learnings from a survey of FDA-approved drugs	6
Exposure–response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma	6
Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study	6